Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAACT P1083: Lopinavir/Ritonavir WHO Weight Band Dosing
NCT01172535Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2010
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Lopinavir/Ritonavir Area Under the Concentration-time Curve at 4 weeks, Maximum Concentration of Lopinavir/Ritonavir at 4 weeks and 5 more. Started Nov 2010; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01172535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172535.